Finance

Lists
Why is KROS down 2.03%?
Dive Deeper
KROS:NASDAQ
Keros Therapeutics Inc
US$9.17
-2.03%
(-0.19) 1D
US$9.17
0.00% (0.00)
After hours
Closed: ኖቬም 9, 4:00:01 ከሰዓት ጂ ኤም ቲ-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for KROS...
Open
US$9.50
High
US$9.87
Low
US$9.10
Mkt. cap
181.82 ሚ
Avg. vol.
164.30 ሺ
Volume
144.15 ሺ
52-wk high
US$22.55
52-wk low
US$9.10
EPS
-US$2.83
Beta
1.13
Shares outstanding
19.62 ሚ
No. of employees
87
Open
US$9.50
High
US$9.87
Low
US$9.10
Mkt. cap
181.82 ሚ
Avg. vol.
164.30 ሺ
Volume
144.15 ሺ
52-wk high
US$22.55
52-wk low
US$9.10
EPS
-US$2.83
Beta
1.13
Shares outstanding
19.62 ሚ
No. of employees
87
News stories
From web sources and news partners
Bloomberg.com
Bloomberg.com
·
ከ3 ሰዓቶች በፊት
Watch S&P 500 Erases Midterm Losses, Bitcoin Bounce
Investing.com
Investing.com
·
ከ3 ሰዓቶች በፊት
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 2.15%
ChartMill
ChartMill
·
ከ6 ሰዓቶች በፊት
Most-Active S&P 500 Stocks in Today's Session
StoneX
StoneX
·
ከ8 ሰዓቶች በፊት
S&P 500 Forecast: SPX rises despite Nvidia’s decline
About Keros Therapeutics Inc
CEO-
Employees87
Founded2015
HeadquartersLexington, ማሣቹሰትስ, ዩናይትድ ስቴትስ
SectorHealth Care
IndustryBiotechnology
Websitekerostx.com
Analyst ratings
Based on 4 analysts giving stock ratings to KROS in the past 3 months
Buy
Buy
2
Hold
2
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for KROS in the last 3 months.
Highest
Current US$9.17
US$20.00 (+118.10%)
Average
US$17.75 (+93.57%)
Lowest
US$16.00 (+74.48%)
Analyst
Recommendation
Action
Price target
Projected
Date
Yun Zhong
Wedbush
Hold
Maintained
US$16.00
+74.5%
11/09/2026
Andres Y. Maldonado
H.C. Wainwright
Buy
Reiterated
US$20.00
+118.1%
11/06/2026
Benjamin Burnett
Wells Fargo
Buy
Maintained
US$18.00
+96.3%
09/02/2026
Jason Zemansky
Bank of America Securities
Hold
Reiterated
US$17.00
+85.4%
08/11/2026
Matt Phipps
William Blair
Hold
Maintained
-
-
08/04/2026
Thomas Smith
Leerink Partners
Buy
Maintained
US$23.00
+150.8%
08/04/2026
Nicholas Lorusso
TD Cowen
Hold
Reiterated
-
-
08/04/2026
Srikripa Devarakonda
Truist Financial
Buy
Maintained
-
-
05/15/2026
Andreas Argyrides
Oppenheimer
Buy
Maintained
US$27.00
+194.4%
03/09/2026
Unknown Analyst
Leerink Partners
Buy
Reiterated
US$30.00
+227.2%
03/06/2026
Tiago Fauth
Raymond James
Buy
Maintained
US$20.00
+118.1%
03/05/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
ዲሴም 2025
ማርች 2026
ጁን 2026
ሴፕቴ 2026
Revenue
385.00 ሺ
367.00 ሺ
-
40.01 ሚ
Cost of goods sold
17.81 ሚ
16.10 ሚ
22.33 ሚ
-
Cost of revenue
17.81 ሚ
16.10 ሚ
22.33 ሚ
-
Research and development expenses
-
-
-
20.49 ሚ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
11.74 ሚ
10.15 ሚ
8.61 ሚ
6.70 ሚ
Operating expense
11.74 ሚ
10.15 ሚ
8.61 ሚ
27.19 ሚ
Total operating expenses
29.56 ሚ
26.24 ሚ
30.94 ሚ
27.19 ሚ
Operating income
-29.17 ሚ
-25.88 ሚ
-30.94 ሚ
12.82 ሚ
Other non operating income
-539.00 ሺ
-
-60.00 ሺ
-168.00 ሺ
EBT including unusual items
-24.98 ሚ
-23.71 ሚ
-28.71 ሚ
14.92 ሚ
EBT excluding unusual items
-24.88 ሚ
-23.71 ሚ
-28.71 ሚ
14.92 ሚ
Income tax expense
-1.51 ሚ
-
-
772.00 ሺ
Effective tax rate
6.06%
-
-
5.17%
Other operating expenses
-
-
-
-
Net income
-23.46 ሚ
-23.71 ሚ
-28.71 ሚ
14.15 ሚ
Net profit margin
-6,093.77%
-6,459.95%
-
35.37%
Earnings per share
-0.86
-1.21
-1.45
0.70
Interest and investment income
4.02 ሚ
2.34 ሚ
2.29 ሚ
2.28 ሚ
Interest expense
-
-
-
-
Net interest expenses
4.02 ሚ
2.34 ሚ
2.29 ሚ
2.28 ሚ
Depreciation and amortization charges
-
-
-
-
EBITDA
-28.77 ሚ
-25.47 ሚ
-30.54 ሚ
13.20 ሚ
Gain or loss from assets sale
1.00 ሺ
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google መተግበሪያዎች